TrialCompass TCL
Find TrialsAI AssistantLetter GeneratorAbout
Back to results
RecruitingPriority 4 · Lower priorityNCT04904146

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

ClinicalTrials.gov

Plain-language summary

This trial is studying Blood tests and testing of analysis of the lymphoma microenvironment in skin and skin barrier and skin microbiology profile. for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 100 Years years
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile. (DIAGNOSTIC_TEST): The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.

Drugs / treatments
Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

At a glance

Phase
Status
Recruiting
Design
Non-randomized, blind
Enrollment target
120 patients
Primary endpoint
Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.
Ages
18 Years to 100 Years
Start date
2021-04-02
Est. completion
2027-04

Locations

0 US sites · 1 total

No US sites currently listed.

Contact

Sponsor
Lund University Hospital (OTHER)
Contact
—

Tags

CTCLany
TrialCompass — Clinical Trial Summary

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

NCT04904146

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying Blood tests and testing of analysis of the lymphoma microenvironment in skin and skin barrier and skin microbiology profile. for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 100 Years years
  • Must be well enough for treatment (adequate performance status)

What's being tested

Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile. (DIAGNOSTIC_TEST): The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.

Drugs / treatments: Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 120 patients

Primary endpoint: Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of serum-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.; Identification of immune cell profile-protein markers.

Ages: 18 Years to 100 Years

Start date: 2021-04-02 | Est. completion: 2027-04

Locations

0 US sites · 1 total

Contact

—

Sponsor: Lund University Hospital (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04904146

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.
TrialCompass

A free tool to help patients, caregivers, and clinicians find and understand clinical trials for T-cell lymphoma.

Explore

  • Find Trials
  • AI Assistant
  • Letter Generator
  • About
  • Share Your Feedback
  • Terms of Use
  • Privacy Policy

Data sourced from ClinicalTrials.gov.

For informational purposes only. Not medical advice — always consult your healthcare team.

Built with care for the rare cancer community.

Data last updated: June 2026

Edit with